| scholarly article | Q13442814 |
| P50 | author | Eric Boerwinkle | Q28050857 |
| Oliver Fiehn | Q28540892 | ||
| Amber L Beitelshees | Q97550459 | ||
| William R Wikoff | Q105758319 | ||
| Rima Kaddurah-Daouk | Q30001911 | ||
| Reginald F. Frye | Q37370763 | ||
| P2093 | author name string | Hongjie Zhu | |
| Rebecca A Baillie | |||
| Yan Gong | |||
| Stephen H Boyle | |||
| Wei Hou | |||
| Julie A Johnson | |||
| Liming Weng | |||
| Rhonda M Cooper-Dehoff | |||
| John G Gums | |||
| Stephen T Turner | |||
| Arlene Chapman | |||
| Mohamed H A Shahin | |||
| P2860 | cites work | Metabolomics reveals amino acids contribute to variation in response to simvastatin treatment | Q21561017 |
| Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure | Q22306384 | ||
| Pharmacogenetics of beta-blockers | Q24644448 | ||
| PLINK: a tool set for whole-genome association and population-based linkage analyses | Q24677407 | ||
| Interplay between lipids and branched-chain amino acids in development of insulin resistance | Q26852310 | ||
| A branched-chain amino acid-related metabolic signature that differentiates obese and lean humans and contributes to insulin resistance | Q28240815 | ||
| Use and abuse of HOMA modeling | Q28263292 | ||
| Standards of medical care in diabetes--2014 | Q28304435 | ||
| A new measure of the effective number of tests, a practical tool for comparing families of non-independent significance tests | Q46095036 | ||
| Normal fasting plasma glucose and risk of type 2 diabetes diagnosis | Q46577421 | ||
| Impact of impaired fasting glucose on cardiovascular disease: the Framingham Heart Study | Q46799954 | ||
| Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble P-selectin levels in hypertensive patients | Q46935519 | ||
| Plasma Amino Acid Levels and Insulin Secretion in Obesity | Q51685623 | ||
| Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? | Q77500219 | ||
| Predictors of development of diabetes mellitus in patients with coronary artery disease taking antihypertensive medications (findings from the INternational VErapamil SR-Trandolapril STudy [INVEST]) | Q80333433 | ||
| Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension | Q81305506 | ||
| Branching out for detection of type 2 diabetes | Q84004337 | ||
| Heart disease and stroke statistics--2012 update: a report from the American Heart Association | Q29547909 | ||
| Metabolite profiles and the risk of developing diabetes | Q29615359 | ||
| SetupX--a public study design database for metabolomic projects | Q30835669 | ||
| Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications | Q33609093 | ||
| Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome | Q33840829 | ||
| Diabetes in the Old Order Amish: characterization and heritability analysis of the Amish Family Diabetes Study | Q33903845 | ||
| Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics | Q34555598 | ||
| Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis | Q34604680 | ||
| Identification of novel candidate genes for type 2 diabetes from a genome-wide association scan in the Old Order Amish: evidence for replication from diabetes-related quantitative traits and from independent populations | Q34685525 | ||
| Metabolomics: a global biochemical approach to drug response and disease | Q34734298 | ||
| Branched-chain and aromatic amino acids are predictors of insulin resistance in young adults | Q36629460 | ||
| Role of mitochondrial dysfunction in insulin resistance | Q37097807 | ||
| Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study | Q37164285 | ||
| Risk factor assessment for new onset diabetes: literature review | Q37194851 | ||
| Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. | Q37304741 | ||
| Relationships between circulating metabolic intermediates and insulin action in overweight to obese, inactive men and women | Q37319222 | ||
| Quality control for plant metabolomics: reporting MSI-compliant studies | Q38502318 | ||
| Identification of quantitative trait loci for glucose homeostasis: the Insulin Resistance Atherosclerosis Study (IRAS) Family Study | Q40500628 | ||
| Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells | Q40787082 | ||
| Association of a peripheral blood metabolic profile with coronary artery disease and risk of subsequent cardiovascular events | Q43155073 | ||
| Impact of body mass index and waist circumference on the long-term risk of diabetes mellitus, hypertension, and cardiac organ damage | Q43496030 | ||
| Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study | Q44113847 | ||
| Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. | Q45145783 | ||
| Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes | Q45199153 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 199-205 | |
| P577 | publication date | 2014-03-13 | |
| P1433 | published in | Circulation: Cardiovascular Genetics | Q15816430 |
| P1476 | title | Is diabetes mellitus-linked amino acid signature associated with β-blocker-induced impaired fasting glucose? | |
| P478 | volume | 7 |
| Q39628839 | A Genetic Response Score for Hydrochlorothiazide Use: Insights From Genomics and Metabolomics Integration |
| Q28074451 | Applying metabolomics to cardiometabolic intervention studies and trials: past experiences and a roadmap for the future |
| Q35900537 | Association of branched and aromatic amino acids levels with metabolic syndrome and impaired fasting glucose in hypertensive patients |
| Q61815750 | Drug-induced diabetes type 2: In silico study involving class B GPCRs |
| Q36652960 | Hypertension pharmacogenomics: in search of personalized treatment approaches |
| Q37078812 | Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine. |
| Q28831476 | Metabolomics enables precision medicine: "A White Paper, Community Perspective" |
| Q36473120 | Pharmacometabolomic Assessments of Atenolol and Hydrochlorothiazide Treatment Reveal Novel Drug Response Phenotypes |
| Q41653342 | Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenolol |
| Q40269056 | Replicated evidence for aminoacylase 3 and nephrin gene variations to predict antihypertensive drug responses. |
| Q49299846 | Sphingolipid Metabolic Pathway Impacts Thiazide Diuretics Blood Pressure Response: Insights From Genomics, Metabolomics, and Lipidomics. |
| Q35701279 | The promise of metabolic phenotyping in gastroenterology and hepatology |
Search more.